Saturday 17 October 2026 Export LBPS’s income statement to Excel — free account

4D pharma PLC Sponsored ADR

Revenue growth for five consecutive years.

Follow LBPS

Alert me

Market cap: $37.2M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 90.69%

Capital & Financial Ratios $m

Market Cap 37.19

Revenue 1.41

Net Income (28.55)

Free Cash Flow (46.25)

Net Debt (7.52)

Current Ratio 5.21

Debt/Equity 0.43

P/E ratio 0.00

Fwd P/E —

P/S ratio 211.23

P/B ratio 9.49

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2018	2019	2020	2021
Cash	1	1	0	12
Receivables	7	7	7	5
Inventory	—	—	—	—
Other	0	—	—	—
	1	1	15	21

	2018	2019	2020	2021
Payables	0	0	2	5
ST’ Debt	—	—	—	—
Other	—	—	—	—
	0	0	6	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	21.70%	38.72%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	45.33%	1.30%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’21	—	—	—	0	1
’21	—	—	—	—	1
’20	—	—	—	—	1
’20	—	—	—	—	0
’19	—	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Feb	May	Aug	Nov	Year
’26	—	—	—	—	—
’21	—	—	—	—	(38)
’21	—	—	—	—	(27)
’20	—	0	0	0	(27)
’20	(28)	—	—	—	(29)
’19	—	0	0	0	(29)
’19	—	—	—	—	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Feb	May	Aug	Nov	Year
’26	—	—	—	—	—
’21	—	—	—	—	(38)
’21	(27)	—	—	—	(27)
’20	—	0	0	0	(27)
’20	(28)	—	—	—	(29)
’19	—	0	0	0	(29)
’19	—	—	—	—	0

Fiscal quarters ending in the months shown.

EPS $

	Feb	May	Aug	Nov	Year
’26	—	—	—	—	—
’21	—	—	—	—	(1.52)
’20	—	(0.06)	(0.10)	(0.10)	(2.34)
’20	(0.09)	—	—	—	(0.50)
’19	—	0.01	(0.07)	(0.06)	(0.46)
’19	—	—	—	—	—
’18	—	—	0.00	(0.01)	(3.86)

Fiscal quarters ending in the months shown.

value withheld pending a data check

Group	Line	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022e
Price, $
Price, $	Low	—	—	—	—	—	—	—	—	—	—	Analyst estimates 2022–2024 Powerpack
	High	—	—	—	—	—	—	—	—	—	—
People
People	Employees	—	—	—	—	—	—	—	—	—	—
	Revenue/emp, $m	—	—	—	—	—	—	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	0	0	1	1
	Gross margin, %	—	—	—	—	0.00	0.00	(572.40)	100.00	100.00	100.00
	EBT	—	—	—	—	(14)	(32)	0	(30)	(31)	(32)
	EBT margin, %	—	—	—	—	0.00	0.00	(5.32)	(11,276.21)	(4,421.45)	(4,451.25)
	Net income	—	—	—	—	(12)	0	0	(30)	(30)	(32)
	Depreciation	—	—	—	—	1	1	0	2	2	1
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.00	0.03	0.00	0.05	0.03
	Earnings	—	—	—	—	(0.19)	(0.42)	(3.86)	(0.46)	(2.34)	(1.52)
	Cash flow	—	—	—	—	(0.24)	(0.35)	(0.04)	(0.44)	(1.91)	(1.79)
	Capex	—	—	—	—	0.00	0.00	0.00	(0.01)	(0.02)	(0.01)
	Free cash flow	—	—	—	—	(0.24)	(0.35)	(0.04)	(0.45)	(1.93)	(1.80)
	Book value	—	—	—	—	1.65	1.45	0.61	0.48	2.73	1.53
	Shares, m	—	—	—	—	65	65	8	65	14	21
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	0.00	0.00	0.00	697.71
	P/B	—	—	—	—	—	—	3.54	21.88	4.36	31.35
	EV/Sales	—	—	—	—	—	—	0.00	0.00	0.00	692.37
	EV/FCF	—	—	—	—	—	—	0.00	(14.97)	(3.57)	(10.81)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	(16)	(23)	0	(29)	(27)	(38)
	Capex	—	—	—	—	(3)	(3)	0	(1)	0	0
	Free cash flow	—	—	—	—	(16)	(23)	0	(29)	(27)	(38)
Balance, $m
Balance, $m	Working capital	—	—	—	—	86	71	1	8	12	28
	Total debt	—	—	—	—	—	0	0	1	1	13
	Net debt	—	—	—	—	(85)	(68)	(1)	(4)	(11)	(8)
	Shareholders’ equity	—	—	—	—	107	94	5	31	39	32
Returns, %
Returns, %	ROA	—	—	—	—	(11.07)	(48.05)	(0.02)	(74.02)	(67.82)	(59.20)
	ROIC	—	—	—	—	0.00	0.00	(6.27)	(91.89)	(77.94)	(96.48)
	ROE	—	—	—	—	(12.11)	(27.48)	(0.03)	(167.65)	(87.26)	(89.48)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2021 · latest quarter Dec 2021 · fundamentals updated 5 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LBPS 4D pharma PLC Sponsored ADR	$37.2M	— (loss-making)	—	+41.64% (above 0%: growing)	n/m	−16,367.69% (below 0%: shrinking)	0.00%	0.00%
EXOZ eXoZymes Inc.	$37.1M	— (loss-making)	—	—	n/m	−3.25% (below 0%: shrinking)	—	0.00%	Compare
FLNA Cassava Sciences, Inc.	$36.8M	— (loss-making)	—	+1,328.04% (above 0%: growing)	n/m	+21.65% (above 0%: growing)	0.00%	0.00%	Compare
LITS Lite Strategy, Inc.	$36.3M	— (loss-making)	— (loss-making)	+647.96% (above 0%: growing)	n/m	+179.28% (above 0%: growing)	0.00%	0.00%	Compare
EDSA Edesa Biotech, Inc.	$36.1M	— (loss-making)	— (loss-making)	−99.88% (below 0%: shrinking)	n/m	−81.24% (below 0%: shrinking)	0.00%	0.00%	Compare
NNVC NanoViricides, Inc.	$35.0M	— (loss-making)	—	—	n/m	−23.94% (below 0%: shrinking)	0.00%	0.00%	Compare
LIANY LianBio Sponsored ADR	$34.2M	0.0×	—	—	n/m	+1,107.59% (above 0%: growing)	0.00%	0.00%	Compare
CRVO CervoMed Inc.	$34.0M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−6.20% (below 0%: shrinking)	100.00%	0.00%	Compare
IRLA Quince Therapeutics, Inc.	$33.8M	— (loss-making)	—	—	n/m	−63.65% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$35.5M	—	—	+274.18%	—	−4.72%	0.00%	0.00%

All 614 Biotechnology stocks →